Filing summary
Entity mismatch: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Targacept, Inc. It covers the quarter and nine months ended September 30, 2014, and was filed November 6, 2014. The summary below describes the filing provided, not a Gyre filing.
Business context and reporting period
Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) therapies. Following unsuccessful trials and discontinued programs, it said it was focused on strategic transactions and adding externally sourced, non-nicotinic opportunities. TC-6499, under exploratory study for diabetic gastroparesis, was its only product candidate under active development. The company had no approved products or product revenue.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $25,000 | $0 | $148,000 | $3.536 million |
| Operating expenses | $5.013 million | $13.146 million | $25.131 million | $37.444 million |
| Operating loss | $4.988 million | $13.146 million | $24.983 million | $33.908 million |
| Net loss | $4.860 million | $12.902 million | $27.995 million | $33.339 million |
| Loss per share, basic and diluted | $0.14 | $0.38 | $0.83 | $0.99 |
| Cash used in operating activities | Not separately reported for the quarter | $31.431 million | $29.444 million |
Amounts are in U.S. dollars; financial statement amounts are shown in thousands where applicable. Gross margin was not meaningful given the absence of material product revenue.
- At September 30, 2014, cash and cash equivalents were $45.707 million and marketable securities totaled $68.839 million, for approximately $114.5 million in cash, cash equivalents and investments. Total assets were $116.121 million.
- Total liabilities were $3.212 million, including $478,000 of current debt; no long-term debt remained. Stockholders’ equity was $112.909 million. Accumulated deficit was $308.628 million.
- Cash and cash equivalents fell $8.778 million from year-end 2013. Operating cash outflow was partly offset by $19.603 million of investing cash inflow, principally net sales and maturities of marketable securities, and $3.050 million of financing cash inflow.
Material changes versus prior comparable periods
- Q3 net loss narrowed to $4.860 million from $12.902 million, principally as R&D expense declined $7.657 million to $2.655 million. The company attributed the reduction mainly to completion of the TC-5619 schizophrenia study and the TC-5214 overactive-bladder study, along with lower R&D personnel and infrastructure costs.
- Nine-month net loss narrowed to $27.995 million from $33.339 million, while operating cash use increased by $1.987 million. Lower R&D and G&A costs were partly offset by the absence of $3.536 million of collaboration revenue recognized in 2013.
- R&D expense fell to $17.143 million for nine months from $28.086 million. Increased TC-6499 study spending partly offset reduced costs for completed or discontinued programs.
- In July 2014, the company reported that the TC-1734 Phase 2b Alzheimer’s trial missed its primary endpoint and the TC-5214 overactive-bladder trial missed one of its two co-primary endpoints. It discontinued further development of both in those indications and recorded an $89,000 impairment of TC-5214-related intellectual property.
Outlook, commentary and key risks
- Management expected approximately $107 million of cash, cash equivalents and investments at December 31, 2014. It said existing resources were expected to fund operations through entry into one or more strategic transactions; elsewhere it said the resources could fund current operations for several years under the existing scope of operations. Strategic alternatives could materially change funding needs.
- The company was exploring strategic alternatives, potentially including a sale, merger, asset disposition, liquidation or combination. No transaction decision had been made, and management provided no timing guidance or assurance a transaction would occur.
- Management planned to continue advancing TC-6499, but its efficacy for diabetic gastroparesis had not been established. The company said it could not reliably forecast development duration or completion costs and expected future losses.
- AstraZeneca terminated its collaboration in October 2014, effective January 2015. Rights to TC-6683 and another compound were to revert to Targacept; the company had no current plan to develop TC-6683 further.
- Key risks include dependence on a single active clinical program, clinical and regulatory failure, inability to secure strategic partners or financing on acceptable terms, disruption or failure of the strategic-alternatives process, limited internal discovery capabilities, and potential dilution from future equity financing. The filing also notes that tax-loss and credit carryforwards may be restricted by ownership-change rules.
- Unusual items included a $3.468 million income tax expense for the nine-month period, associated with excess stock-option tax deductions following completion of a federal tax examination; the examination did not change federal net operating loss carryforwards. The filing reports a $3.412 million financing cash-flow benefit related to excess tax deductions.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Targacept’s, not Gyre Therapeutics’.
- Check subsequent disclosures for the outcome and terms, if any, of the strategic-alternatives process and its impact on cash runway.
- Verify TC-6499 study progress, results and remaining development costs; it was the only actively developed candidate described.
- Confirm the effective completion of the AstraZeneca termination and reversion of licensed rights in January 2015.
- Assess cash burn and liquidity against the forecast, including the company’s dependence on new strategic arrangements or financing.